Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, reports on the latest steps by government agencies to drive the adoption of innovative MedTech.
Medical device innovators across the UK are set to benefit from a major shift in how the NHS adopts and reimburses new technologies. The National HealthTech Access Programme (NHAP), announced as part of the government’s 10 Year Health Plan, aims to tackle a long‑standing challenge: cutting‑edge MedTech often reaches patients unevenly, slowly, or not at all. The new programme promises a more predictable, transparent, and nationally consistent route into the health system – one that suppliers have been calling for over many years.
The NHAP, previously known as the Rules Based Pathway, is a joint initiative involving medicines and MedTech assessor NICE, the Department of Health and Social Care, NHS England, and the medicines and medical devices regulator the MHRA and the Office for Life Sciences. At its core is a significant expansion of NICE’s Technology Appraisal (TA) programme. For the first time, selected high‑impact medical devices, diagnostics and digital tools will be appraised and reimbursed in the same way as medicines. Once approved, these technologies will be mandated for adoption across the NHS in England and Wales.
For suppliers, this represents a step‑change. A positive TA will no longer simply be a badge of quality – it will unlock guaranteed national uptake, consistent commissioning, and a clearer commercial pathway. NICE’s Chief Executive, Professor Jonathan Benger, describes the reform as extending the organisation’s founding mission: ending the postcode lottery, this time for MedTech rather than medicines.
Early Topics Signal the Programme’s Ambition
NICE has already announced the first two technologies to enter the NHAP: capsule sponge tests for detecting oesophageal cancer and AI‑enabled tools for analysing prostate and breast cancer tissue samples.
Capsule sponge tests – sometimes referred to as the “pill on a string” – offer a minimally invasive alternative to endoscopy for detecting Barrett’s oesophagus and early‑stage oesophageal cancer. Early diagnosis is critical: five‑year survival rates can reach 95% when the disease is caught early, compared with as low as 40% at later stages. By reducing reliance on endoscopy, the technology also helps free capacity in overstretched diagnostic services.
AI pathology tools represent another high‑impact opportunity. By analysing digital tissue images, highlighting suspicious areas and grading tumours, these systems can reduce routine workload, improve reporting consistency and accelerate prioritisation of high‑risk cases. For the NHS, the benefits extend beyond efficiency: AI‑supported diagnostics could help reduce geographical variation in access to specialist expertise and support national cancer targets.
Two further technologies – tools for detecting endometrial cancer and AI for analysing chest X‑rays in suspected lung cancer – have been referred to NICE pending additional evidence.
What the NHAP Means for Suppliers
For medical device and digital health companies, NICE suggests the NHAP offers:
- A clearer, more predictable route to national adoption, reducing the need for region‑by‑region sales strategies.
- A reimbursement mechanism for non‑pharmaceutical technologies, long seen as a missing piece in the UK market.
- A stronger incentive to generate robust clinical and economic evidence, aligned with NICE’s established appraisal standards.
- A more innovation‑friendly environment, as the programme forms part of a wider open‑innovation strategy to strengthen the UK HealthTech sector.
The NHAP is one of three major commitments NICE will deliver under the 10 Year Health Plan, alongside updated guidance to support smarter spending and parallel decision‑making to accelerate access.
For suppliers, the message is clear: the UK is reshaping its HealthTech landscape, and those with high‑impact, evidence‑backed technologies stand to gain from a more streamlined and equitable route into the NHS.
The author used AI in preparing this article. Comments upon or questions about this article can be addressed to chris.whitehouse@whitehousecomms.com.
